Hajdu-Cheney Syndrome

Hajdu–Cheney syndrome is a very rare, inherited connective-tissue and bone disorder. It is caused by a change (mutation) in one copy of a gene called NOTCH2. This change makes the NOTCH2 signal too strong in bone cells. Over time, bones become thin and fragile (fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?). Bone at the tips of the fingers and toes may dissolve (acro-osteolysis). The skull and face can have special signs such as extra small bones in the skull sutures (Wormian bones) and changes at the skull base. Joints can be loose. Teeth may loosen early. Short stature and spine curves can appear. The condition can run in families in an autosomal dominant way, but it also often starts as a new (de novo) mutation in a child with unaffected parents. BioMed CentralNaturePubMed

Other names

Hajdu–Cheney syndrome is also known by several older names that describe its bone and dental features. These include Cheney syndrome, acro-osteolysis with fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?, arthro-dento-osteodysplasia, and acrodento-osteodysplasia. Some authors simply use “Hajdu–Cheney” or “HCS.” The names reflect the key problems: bone loss at the finger and toe tips (acro-osteolysis), poor bone strength through the skeleton (fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?), joint laxity (arthro-), and early tooth loosening or loss (dento-). You may also see “Orpha 955,” which is the Orphanet listing number for this condition. Using “Hajdu–Cheney syndrome” is preferred today because it unifies the diagnosis? and links it to the known cause, a NOTCH2 gene mutation. WikipediaPubMed

Types

Because one gene is responsible, there are no official “clinical subtypes” like Type 1 or Type 2. Still, doctors and researchers sometimes group cases in practical ways:

1. By inheritance

• Familial HCS: one parent has HCS and passes it to a child.

• De novo HCS: the child is the first in the family with HCS due to a new mutation. PMC

2. By age of main features

• Childhood-onset skeletal signs: acro-osteolysis, skull changes, short stature.

• Adolescent/adult progression: fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?, fractures, spine curves, skull-base issues such as basilar invagination or Chiari I. PMC+1

3. By gene change location

• NOTCH2 truncating variants in the terminal region (often exon 34) that remove/alter the PEST domain, leading to increased NOTCH2 activity and more bone resorption. (Clinically they all cause a similar picture.) NatureScienceDirect

Takeaway: HCS is one disease with variable severity over time. The “type” is usually described by inheritance (familial vs de novo) and by where the mutation is within NOTCH2’s final exon.

Causes

HCS has one core cause—a heterozygous, gain-of-function NOTCH2 mutation—but many mechanistic drivers and modifiers explain how and why bones and other tissues are affected. Each item below is a short, plain-English paragraph.

1. NOTCH2 truncating mutation (heterozygous)
   A single altered copy of NOTCH2 is enough to cause disease. The mutation truncates the tail of the protein and removes a built-in “off-switch” (PEST sequence), so signaling stays high. This drives bone loss. Nature

2. Loss of the PEST domain
   The PEST domain normally tags NOTCH2 for breakdown. When it is missing, the protein lasts longer and signals more. Stronger NOTCH signaling shifts bone balance toward resorption. Nature

3. Exon 34 hotspot
   Many HCS mutations cluster in exon 34 of NOTCH2. These changes escape normal RNA quality control and produce an overactive protein. ScienceDirect

4. Autosomal dominant inheritance
   If a parent has HCS, each child has a 50% chance to inherit it. This pattern explains family clusters. PMC

5. De novo mutation
   In many families, the mutation is new in the child. Parents are unaffected. De novo events explain the rarity and sudden appearance in a family. PMC

6. Increased osteoclast activity
   Overactive NOTCH2 boosts signals that favor osteoclast formation and function. Osteoclasts break down bone, so bones thin and finger/toe tips dissolve. PMCBioMed Central

7. Reduced effective osteoblast function
   Notch signaling also changes osteoblast lineage decisions. Even if osteoblasts are present, the balance tips toward bone loss. BioMed Central

8. RANK–RANKL–OPG axis shift (inference from bone biology)
   Stronger Notch signals can intersect with RANKL pathways that drive osteoclasts. More RANKL effect means more bone resorption. (Mechanistic inference based on Notch–bone crosstalk.) BioMed Central

9. Generalized skeletal fragility (fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?)
   With time, overall bone density drops. Low density raises fracture? risk and worsens deformities. PubMed

10. Acro-osteolysis process
    The terminal phalanges are very active, small bones. In HCS they are especially sensitive to bone resorption, so their tips shorten. PMC

11. Skull-base remodeling
    Excessive resorption and altered growth at the skull base can cause basilar invagination and crowding where the brainstem and upper spine meet. PMC

12. Joint laxity and connective-tissue weakness?
    Abnormal Notch signaling in connective tissue can loosen ligaments. Loose joints change mechanics and raise injury and pain? risk. PubMed

13. Dental and periodontal tissue effects
    Periodontal tissue may be weak. Teeth can loosen and fall out early. Jaw bones can remodel abnormally. National Organization for Rare Disorders

14. Spine growth and remodeling imbalance
    Vertebrae with low bone mass and altered shapes make scoliosis and kyphosis more likely. PMC

15. Cranial suture biology
    Wormian bones reflect disturbed sutural growth and bone remodeling in the skull. PubMed

16. Hearing pathway involvement
    Bone and connective-tissue changes around the ear can lead to hearing loss in some patients. PubMed

17. Renal? cysts/urinary tract involvement
    Some individuals have kidney cysts. This shows that NOTCH2 changes can affect other organs. PubMed

18. Cardiovascular developmental effects
    Occasional heart or vascular anomalies are reported, consistent with NOTCH roles in vessel and heart development. PubMed

19. Neurologic crowding from skull-base change
    Basilar invagination and Chiari I can compress neural tissue, causing headaches, imbalance, or other neuro signs. PMC

20. Fracture?-pain?-deconditioning cycle
    Fragile bones lead to fractures, pain?, and less movement. Less movement weakens bone and muscle further, worsening function over time. (Clinical reasoning consistent with fracture? risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।" data-rx-term="osteoporosis" data-rx-definition="Osteoporosis means weak, fragile bones with higher fracture risk. সহজ বাংলা: হাড় দুর্বল হয়ে ভাঙার ঝুঁকি বেশি।">osteoporosis?.) PubMed

Common symptoms and signs

1. Bone pain? or tenderness?
   Thin bones and micro-fractures can hurt, especially in the spine, hips, or long bones. PubMed

2. Shortened finger and toe tips
   Acro-osteolysis leads to shorter, bulbous fingertips and toes. Fine motor skills may become harder. MedlinePlus

3. Frequent fractures or stress fractures
   Low bone density raises the chance of fractures after small injuries. PubMed

4. Short stature
   Many children with HCS grow more slowly and remain shorter than peers. PubMed

5. Loose joints (joint laxity)
   Ligaments can be lax, causing hypermobility, sprains, and joint pain?. PubMed

6. Spine curves (scoliosis/kyphosis)
   Weak vertebrae and ligament? laxity can bend the spine. pain?: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">Back pain? and fatigue? may follow. PMC

7. Skull and facial differences
   Wormian bones, small maxilla, and skull-base changes can alter head shape and bite. PubMed

8. Headaches or neck symptoms
   If basilar invagination or Chiari I is present, headaches, neck pain?, or balance problems may occur. PMC

9. Early tooth loosening or loss
   Periodontal tissues are fragile; teeth may become loose and fall out earlier than normal. National Organization for Rare Disorders

10. Hearing loss
    Some people have conductive or sensorineural hearing loss due to bone and soft-tissue changes around the ear. PubMed

11. Flat feet and foot pain?
    Ligament? laxity and bone loss in the feet can cause arch collapse and aching. (Clinical reasoning aligned with HCS joint laxity.) PubMed

12. Delayed motor skills
    Low muscle tone, joint laxity, and skeletal issues can slow gross and fine motor milestones. MedlinePlus

13. Fatigue? with activity
    Weak bones, spine curves, and pain? reduce endurance for walking or climbing. (Clinical reasoning.) PubMed

14. Facial/dental crowding or malocclusion
    Jaw development differences can change the bite and tooth spacing. PubMed

15. Anxiety about fractures and appearance
    Chronic health issues can cause worry and low mood; psychological support can help. (General clinical principle.)

Diagnostic tests

A) Physical examination

1. General growth and body proportion check
   Measure height, weight, and arm-span. Doctors look for short stature and compare to growth charts over time. PubMed

2. Hand and foot inspection
   The doctor checks for bulbous fingertips, nail changes, and loss of finger/toe tip length—classic acro-osteolysis signs. PMC

3. Spine and posture exam
   Forward bend and posture checks help detect scoliosis or kyphosis and any tender points along the spine. PMC

4. Joint laxity scoring
   A Beighton-style hypermobility score helps document ligament laxity that is common in HCS. (Hypermobility assessment is standard for laxity.) PubMed

5. Craniofacial/dental inspection
   Facial profile, palate shape, gum health, and tooth stability are examined for early loosening and malocclusion. National Organization for Rare Disorders

B) Manual/bedside functional tests

6. Grip and pinch strength
   Simple dynamometer or clinician-assessed grip/pinch identifies loss of fine motor function due to acro-osteolysis or pain. (Standard functional test.) jhandsurg.org

7. Gait and balance tests
   Toe-heel walking and simple balance stands can reveal pain limits, weakness, or cerebellar signs if Chiari is present. PMC

8. Spinal flexibility maneuvers
   Forward flexion and extension note stiffness or pain and help track scoliosis impact over time. PMC

9. Jaw opening and bite function
   Range of mandibular motion and bite strength are observed due to dento-alveolar changes. PubMed

10. Hearing screening (bedside)
    Whisper test and tuning fork tests (Rinne/Weber) screen for hearing loss before formal audiology. PubMed

C) Laboratory and pathological tests

11. Serum calcium, phosphate, alkaline phosphatase, vitamin D, and PTH
    These rule out other causes of bone loss and help guide supportive care. HCS usually has normal basic labs but severe osteopenia by imaging. (Work-up of osteoporosis.) BioMed Central

12. Bone turnover markers (e.g., CTX, P1NP)
    Markers can show high resorption activity and help monitor osteoporosis treatments, if used. (General bone medicine practice.) BioMed Central

13. Genetic testing: NOTCH2 sequencing and deletion/duplication analysis
    This is the key diagnostic test. Finding a pathogenic NOTCH2 variant confirms HCS. Parental testing clarifies inheritance. NaturePubMed

14. Differential diagnosis panel (if features overlap)
    Testing for osteogenesis imperfecta genes or collagen markers may be considered when the picture is unclear. (To distinguish from other skeletal dysplasias.) BioMed Central

15. Basic kidney and thyroid screens
    Renal function and thyroid tests help identify comorbidities or contributors to bone health and growth. (Comorbidity screening.) PubMed

D) Electrodiagnostic and related physiologic tests

16. Pure-tone audiometry and/or auditory brainstem response (ABR)
    Formal hearing tests measure the degree and type of hearing loss and guide hearing support. PubMed

17. Electrocardiogram (ECG)
    An ECG checks heart rhythm if there are symptoms or a known heart issue, given occasional cardiovascular involvement in HCS. PubMed

18. Polysomnography (sleep study) if indicated
    Craniofacial and skull-base changes can narrow airways; testing helps diagnose sleep-disordered breathing. (Clinical reasoning consistent with craniofacial disorders.)

E) Imaging tests

19. X-rays of hands and feet
    This is often the most characteristic study. It shows the transverse band of acro-osteolysis at the distal phalanges and other small-bone changes. PubMedRadiology Cases

20. Skull X-ray or CT
    These can reveal Wormian bones, skull-base changes, and sinus or jaw differences. PubMed

21. Cervical spine MRI
    MRI looks for basilar invagination, Chiari I malformation, or spinal cord compression. It is important when headaches, neck pain, or neuro signs are present. PMC

22. Whole-spine X-rays
    Standing films measure scoliosis or kyphosis and track changes over time. PMC

23. Dual-energy X-ray absorptiometry (DXA)
    DXA measures bone mineral density to document osteoporosis and monitor therapy. PubMed

24. Echocardiogram (heart ultrasound)
    If a murmur, symptoms, or known heart anomaly exists, echo evaluates structure and function. PubMed

25. Renal ultrasound
    Screens for kidney cysts or other anomalies that can occur in some individuals with HCS. PubMed

Non-pharmacological treatments

1) Baseline fracture-risk assessment and a “bone-safe” living plan (Physiotherapy team lead)
A therapist evaluates posture, balance, prior falls, home hazards, and footwear. The goal is to reduce falls and impact forces that can cause fractures in fragile bone. The plan removes tripping hazards, improves lighting, recommends shock-absorbing shoes, and adds grab bars and railings. Mechanism: cutting fall risk lowers fracture risk; limiting axial and torsional loads reduces micro-damage in osteoporotic bone. Benefits: fewer injuries, more confidence in daily activities, and safer independence.

2) Postural training and spinal alignment drills (Physiotherapy)
Gentle wall-angel work, scapular setting, chin tucks, and pelvis-neutral training improve sagittal balance. Purpose: reduce spinal pain and slow curve progression. Mechanism: improved muscle endurance and proprioception spread loading more evenly across vertebrae and discs. Benefits: less fatigue, better breathing mechanics, and safer lifting.

3) Low-impact strengthening (Physiotherapy)
Closed-chain exercises (sit-to-stand, mini-squats to a box, step-ups), resistance bands, and water-based strengthening maintain muscle around hips, knees, and spine without high impact. Purpose: guard bone with stronger muscles and better joint control. Mechanism: muscles act as “shock absorbers,” decreasing peak bone stress; modest, safe mechanical strain may also support bone maintenance. Benefits: easier transfers, better gait, and stability.

4) Hip abductor and extensor program (Physiotherapy)
Targeted gluteal strengthening (side-lying abductions, bridges, standing hip extension with bands). Purpose: reduce Trendelenburg gait and falls. Mechanism: stronger lateral hip control stabilizes the pelvis during single-leg stance. Benefits: safer walking, stairs, and outdoor mobility.

5) Core stabilization (Physiotherapy)
Transversus abdominis activation, dead-bug variants, and bird-dog with strict form. Purpose: improve trunk control to protect the spine. Mechanism: a stable trunk limits shear on vertebrae and reduces pain. Benefits: better endurance for sitting/standing and lifting essentials.

6) Balance and reactive-step training (Physiotherapy)
Tandem stance, single-leg balance near support, and quick step training. Purpose: prevent falls. Mechanism: improves vestibular, visual, and proprioceptive integration and stepping reactions. Benefits: fewer near-falls, greater confidence outdoors.

7) Gait optimization and assistive device fitting (Physiotherapy)
Assessment for canes, trekking poles, or walkers; cadence and step-width coaching. Purpose: improve stability and reduce joint load. Mechanism: widening base of support and off-loading weak limbs reduces peak forces. Benefits: safer community mobility and longer walking distance.

8) Hand and foot protection program (Physiotherapy/OT)
Finger and toe tip acro-osteolysis is sensitive to pressure. Use padded gloves for chores, wide toe-box shoes, silicone toe caps, and activity pacing. Purpose: limit micro-trauma to distal phalanges. Mechanism: pressure distribution reduces nociception and local bone stress. Benefits: less pain, better dexterity, and fewer skin injuries.

9) Custom orthoses and spinal bracing when indicated (Physiotherapy/OT/Orthotist)
Soft lumbar supports for painful tasks, ankle-foot orthoses for instability, or wrist splints for overuse. Purpose: temporary support during flares or rehab phases. Mechanism: external stabilization limits harmful motion and load. Benefits: enables safer training and ADLs.

10) Aquatic therapy (Physiotherapy)
Shallow-water walking, gentle resistance using water drag. Purpose: train strength and endurance with joint- and bone-friendly loading. Mechanism: buoyancy reduces impact while providing resistance. Benefits: improved fitness with low pain.

11) Breathing and chest mobility work (Physiotherapy)
Thoracic expansion drills, diaphragmatic breathing, and pectoral stretches. Purpose: counter kyphosis-related restriction. Mechanism: improves rib mobility and oxygenation. Benefits: better stamina and pain relief.

12) Pain-relieving physical modalities (Physiotherapy)
Short courses of heat for muscle spasm, ice after activity, and TENS for neuropathic-like pain. Purpose: symptom control so patients can train. Mechanism: thermal modulation and gate-control analgesia. Benefits: higher adherence and quality of life.

13) Gentle flexibility with protection rules (Physiotherapy)
Short, pain-free stretches for pectorals, hip flexors, calves; avoid end-range spinal flexion/rotation. Purpose: keep ROM for function. Mechanism: reduces stiffness without stressing fragile vertebrae. Benefits: easier dressing, reaching, walking.

14) Functional task practice (Physiotherapy/OT)
Rehearse transfers, floor recovery, stair skills, and object handling with “hip-hinge” mechanics. Purpose: translate gains to daily life. Mechanism: task-specific motor learning. Benefits: independence and safety.

15) Periodic re-screen and program progression (Physiotherapy)
Update loads, balance challenges, and endurance targets every 6–12 weeks. Purpose: keep stimulus appropriate and safe. Mechanism: progressive overload without impact. Benefits: steady gains, fewer plateaus.

16) Stress-management with mindfulness or paced-breathing (Mind-Body)
Purpose: reduce central sensitization and muscle guarding. Mechanism: lowers sympathetic tone and pain catastrophizing. Benefits: better sleep, pain control, and adherence.

17) Gentle yoga or tai chi with osteoporosis precautions (Mind-Body)
Purpose: improve balance, flexibility, and mood. Mechanism: slow, controlled movement enhances proprioception and core activation; emphasis on neutral spine reduces shear. Benefits: fewer falls, calmer mind.

18) Cognitive behavioral skills for chronic pain (Mind-Body)
Purpose: reframe unhelpful thoughts and improve coping. Mechanism: cognitive restructuring reduces perceived pain intensity and disability. Benefits: sustained function despite symptoms.

19) Sleep hygiene plan (Mind-Body)
Purpose: improve recovery and pain thresholds. Mechanism: consistent sleep supports hormone balance and tissue repair. Benefits: better energy and participation in rehab.

20) “Gene-informed” self-care literacy (Mind-Body/Education)
Plain education on NOTCH2-driven bone turnover and why heavy impact is risky. Purpose: improve decisions day-to-day. Mechanism: understanding biology builds adherence. Benefits: fewer injuries and better long-term outcomes.

21) Patient and family education on red-flags (Education)
Teach signs of cranio-cervical issues (severe occipital headaches, vomiting, new weakness), jaw infections, and atypical fractures. Purpose: rapid escalation when needed. Mechanism: early detection prevents complications. Benefits: safer care.

22) Dental and periodontal prevention bundle (Education/Environment)
Three-month cleanings, daily flossing, high-fluoride toothpaste, soft brush, and mouthguards for bruxism. Purpose: slow periodontal bone loss and preserve teeth. Mechanism: bacterial control reduces alveolar resorption risk. Benefits: better nutrition and speech. PubMed

23) Nutrition coaching for bone health (Education)
Adequate protein, calcium, vitamin D, and overall energy intake; distribute protein across meals. Purpose: support bone remodeling and muscle repair. Mechanism: substrate sufficiency for collagen matrix and mineralization. Benefits: improved training response and bone maintenance.

24) School/workplace accommodations (Education/Environment)
Ergonomic chairs, adjustable desks, reduced carrying loads, elevator access, and flexible schedules for therapy visits. Purpose: protect the skeleton while enabling participation. Mechanism: load management prevents flares. Benefits: sustained education and employment.

25) Safety plan for community mobility (Education/Environment)
Route planning to avoid stairs, wet floors, and night travel without lighting; use of rideshare on flare days. Purpose: minimize fall exposures. Mechanism: hazard avoidance. Benefits: fewer accidents and more independence.

Drug treatments

Doses are typical adult starting points; individualization and pediatric dosing must be done by the treating clinician.

1) Alendronate (bisphosphonate)
Typical dose: 70 mg orally once weekly in the morning with water; remain upright 30 min. Purpose: anti-resorptive to increase BMD and cut fracture risk. Mechanism: inhibits farnesyl pyrophosphate synthase in osteoclasts → reduced bone resorption. Side effects: esophagitis, GI upset, rare atypical femur fracture or osteonecrosis of the jaw (ONJ). Evidence: bisphosphonates can help spinal BMD in HCS, although acro-osteolysis may continue. BioMed Central

2) Risedronate (bisphosphonate)
Dose: 35 mg weekly or 150 mg monthly. Purpose: anti-resorptive alternative when alendronate not tolerated. Mechanism/benefits similar. Side effects: GI irritation, musculoskeletal pain, rare ONJ.

3) Zoledronic acid (IV bisphosphonate)
Dose: 5 mg IV once yearly (adult); pediatric regimens differ. Purpose: potent anti-resorption for adherence issues. Mechanism: long-acting osteoclast inhibition. Side effects: transient flu-like reaction, hypocalcemia, rare ONJ; check renal function. Evidence in HCS for vertebral BMD support in case series. BioMed Central

4) Pamidronate (IV bisphosphonate; often used in children with fragility)
Dose: cycles (e.g., 1 mg/kg/day for 3 days every 3–4 months—specialist protocols vary). Purpose: improve pediatric BMD and pain. Side effects: hypocalcemia, fever, bone pain post-infusion; dental vigilance for ONJ.

5) Denosumab (RANKL inhibitor mAb)
Dose: 60 mg subcutaneously every 6 months (adult). Purpose: strong anti-resorptive to raise BMD. Mechanism: neutralizes RANKL → blocks osteoclast formation/activity. Side effects: hypocalcemia, cellulitis, ONJ risk; rebound bone loss if stopped abruptly. Evidence: case report in HCS showed BMD gain but acro-osteolysis often continued, so expectations must be realistic. PubMedPMC

6) Teriparatide (PTH 1-34, anabolic)
Dose: 20 µg SC daily up to 24 months lifetime. Purpose: stimulate new bone formation in severe osteoporosis. Mechanism: intermittent PTH signaling increases osteoblast activity. Side effects: hypercalcemia, dizziness; avoid in patients with open epiphyses or prior skeletal radiation. In HCS, benefit is case-based and may not halt acro-osteolysis. PMC

7) Abaloparatide (PTHrP analog, anabolic)
Dose: 80 µg SC daily up to 24 months. Purpose: anabolic alternative to teriparatide. Mechanism: PTH1 receptor agonism with osteoblast stimulation. Side effects: nausea, dizziness, hypercalciuria; similar caveats as teriparatide.

8) Romosozumab (sclerostin inhibitor mAb, anabolic + anti-resorptive)
Dose: 210 mg SC monthly for 12 months. Purpose: rapid BMD gains in very high-risk osteoporosis; evaluate CV risk. Mechanism: lifts the “brake” on Wnt signaling → increases formation and reduces resorption. Evidence: exploratory case report suggests potential utility in HCS but data are early; not a cure. Side effects: injection site reactions; boxed warning for MI/stroke risk in the prior year. PubMedSpringerLink

9) Calcitonin (nasal or SC)
Dose: 200 IU intranasal daily (variable). Purpose: short-term analgesic effect for acute vertebral fracture pain; modest anti-resorptive. Side effects: rhinitis, nausea.

10) Raloxifene (SERM; postmenopausal only)
Dose: 60 mg daily. Purpose: vertebral fracture risk reduction when other options unsuitable. Mechanism: estrogen receptor modulation reduces resorption. Side effects: hot flashes, VTE risk.

11) Hormone therapy (estrogen ± progestin; postmenopausal)
Dose: individualized lowest effective dose. Purpose: bone protection when also treating menopausal symptoms. Side effects: VTE, stroke, breast tenderness; specialist decision.

12) Cholecalciferol/Vitamin D3 (adjunct)
Dose: commonly 1000–2000 IU/day; titrate to 25-OH D 30–50 ng/mL. Purpose: enable anti-resorptives/anabolics to work safely. Side effects: rare hypercalcemia if overdosed.

13) Calcium (diet first; supplement if needed)
Dose: total 1000–1200 mg elemental/day from food + pills if short. Purpose: ensure mineral supply for remodeling during therapy. Side effects: constipation; space from bisphosphonates.

14) Acetaminophen
Dose: up to 3 g/day in divided doses (lower if liver risk). Purpose: baseline analgesia with low GI/renal risk. Side effects: hepatotoxicity at high doses.

15) NSAIDs (e.g., naproxen 250–500 mg bid with food)
Purpose: pain and inflammation control during flares or peri-surgery. Side effects: GI bleed, renal effects; use with caution in fragile bone and dental procedures (bleeding risk), and avoid if contraindicated.

Key takeaways: anti-resorptives (bisphosphonates, denosumab) and anabolics (teriparatide, abaloparatide, romosozumab) are used in HCS to improve BMD, but published cases show acro-osteolysis can still progress; set expectations and monitor closely. PubMedPMC

Dietary molecular supplements

1) Protein (diet first; whey if needed)
Dose: ~1.0–1.2 g/kg/day, divided. Function/mechanism: provides amino acids for collagen matrix and muscle, supporting bone through mechanotransduction. Benefit: better rehab response and fall reduction via stronger muscle.

2) Vitamin D3
See above for dosing. Mechanism: improves calcium absorption and mineralization. Benefit: reduces hypocalcemia risk with denosumab/zoledronate.

3) Calcium (diet-dominant)
Prefer dairy/fortified foods; supplement only to fill gaps. Mechanism: substrate for hydroxyapatite crystals. Benefit: supports anti-osteoporotic drugs.

4) Vitamin K2 (menaquinone-7)
Dose: often 90–180 µg/day (country-specific guidance varies). Mechanism: carboxylates osteocalcin, aiding mineral binding. Benefit: possible small BMD support; evidence is mixed—use as adjunct.

5) Magnesium
Dose: ~200–400 mg/day (glycinate/citrate forms). Mechanism: cofactor in bone mineral metabolism; may reduce cramps. Benefit: supports muscle function for balance.

6) Omega-3 fatty acids (EPA/DHA)
Dose: ~1 g/day combined EPA+DHA. Mechanism: anti-inflammatory signaling; may lower bone resorption markers modestly. Benefit: joint comfort and cardiometabolic support.

7) Collagen peptides
Dose: 5–10 g/day. Mechanism: provides glycine/proline for collagen; small studies show improvements in bone turnover markers when paired with calcium/Vit D. Benefit: potential adjunct for bone quality.

8) Zinc
Dose: 8–15 mg/day total from diet/supplement. Mechanism: cofactor for collagen cross-linking enzymes and alkaline phosphatase. Benefit: supports wound healing (dental).

9) Boron
Dose: 1–3 mg/day. Mechanism: influences calcium/magnesium handling and vitamin D metabolism. Benefit: small adjunctive effect; avoid excess.

10) Prunes or dried plum polyphenols (food-based)
Serving: ~50–100 g/day. Mechanism: polyphenols may reduce oxidative stress and resorption markers. Benefit: gentle, food-first strategy for bone health.

Regenerative/anabolic or immune-modulating” therapies

(Realistic status: some are approved for osteoporosis, none are proven to stop HCS acro-osteolysis; stem-cell and gene therapies remain investigational.)

1) Teriparatide (PTH 1-34) – see above dosing. Function: stimulates osteoblasts to lay new bone; mechanism is intermittent PTH receptor activation. Benefit: vertebral BMD improvement in severe osteoporosis; caution in growing skeletons. PMC

2) Abaloparatide – see above. Similar anabolic mechanism with different receptor kinetics; short approved course then switch to anti-resorptive to maintain gains.

3) Romosozumab – monthly for 12 months. Mechanism: sclerostin blockade augments Wnt signaling (formation) and reduces resorption. Evidence in HCS: exploratory reports only; monitor cardiovascular risk. PubMedSpringerLink

4) Denosumab – potent anti-resorptive monoclonal antibody. In HCS, BMD gains can occur but acro-osteolysis may continue; plan safe transition when stopping to avoid rebound. PubMed

5) Mesenchymal stem-cell (MSC) therapy – investigational. No approved dosing for HCS; theoretical mechanism is osteogenic support and paracrine signaling. Use only in regulated clinical trials.

6) Gene-targeted strategies (NOTCH pathway modulation) – experimental. No clinical dosing or products for HCS today. Research explores safely tempering overactive NOTCH2 signaling in bone; not ready for routine care.

Surgeries

1) Cranio-cervical decompression ± occipito-cervical fusion
Why: treat basilar invagination or Chiari-like compression causing headaches, vomiting, weakness, or myelopathy. Goal: protect the brainstem and spinal cord and stabilize the junction.

2) Spinal fusion or instrumentation for severe scoliosis/instability
Why: progressive curves or vertebral collapse with pain or neurologic risk. Goal: realign and stabilize to prevent further damage and improve function.

3) Hand/foot corrective procedures
Why: painful telescoping digits or instability from acro-osteolysis. Goal: pain relief, function, and protection of soft tissues; procedures individualized.

4) Orthognathic/dental surgery and periodontal grafting
Why: severe malocclusion, jaw dysfunction, or progressive periodontal bone loss. Goal: improve chewing, speech, and tooth retention; coordinate with bone-active medications to lower ONJ risk. MDPI

5) Hearing restoration procedures (e.g., ossiculoplasty or cochlear implant, when indicated)
Why: moderate to severe conductive or sensorineural hearing loss impacting communication. Goal: improve hearing and quality of life.

 Prevention tips

1. Eliminate home fall hazards and add grab bars/rails.

2. Wear cushioned, grippy shoes; use toe caps if needed.

3. Keep calcium, vitamin D, and protein intake adequate.

4. Follow a low-impact, balance-focused exercise plan.

5. Avoid high-impact sports, heavy spinal flexion/twist, and contact activities.

6. Maintain dental hygiene and 3-monthly dental visits. PubMed

7. Vaccinate on schedule and treat infections early (protects overall health for surgery readiness).

8. Review medications that increase falls (sedatives); deprescribe when safe.

9. Protect hands/feet during chores with padding and good gloves.

10. Keep scheduled bone-density scans and specialist reviews.

When to see doctors urgently

• Severe occipital headache, neck pain, vomiting, imbalance, fainting, new weakness, or numbness (possible cranio-cervical compression).

• New back pain after a minor event, height loss, or posture change (possible vertebral fracture).

• Sudden limb pain or deformity after a simple twist or fall (fracture).

• Jaw pain, non-healing mouth sores, or exposed bone if you use anti-resorptives (possible ONJ). MDPI

• Rapid tooth loosening or gum infections. PubMed

What to eat and what to avoid

Eat more: 1) Dairy/fortified milk or calcium-set tofu; 2) Small fish with bones (sardines); 3) Leafy greens; 4) Eggs and vitamin-D-fortified foods; 5) Lean proteins (fish, poultry, legumes); 6) Nuts/seeds for magnesium; 7) Fruit/veg rich in polyphenols (berries, prunes); 8) Whole grains; 9) Plenty of water; 10) Olive-oil-style fats.

Limit/avoid: 1) Smoking; 2) Heavy alcohol; 3) Very high salt intake; 4) Sugary sodas; 5) Crash diets; 6) Excess caffeine without dairy; 7) Ultra-processed foods; 8) Repeated high-impact sports; 9) Unregulated “bone” supplements; 10) Long bed rest.

Frequently asked questions

1) What causes HCS?
Pathogenic changes in the NOTCH2 gene that heighten Notch signaling, which increases bone resorption and disrupts formation. BioMed CentralPMC

2) Is it always inherited?
Often autosomal dominant, but new (sporadic) mutations occur. PMC

3) Why do fingertips shorten?
Acro-osteolysis is progressive loss of bone at the distal phalanges due to imbalanced remodeling. PMC

4) Can medicines stop acro-osteolysis?
Current reports show drugs can improve overall BMD, but acro-osteolysis may still progress. PubMed

5) Which bone drugs are used most?
Bisphosphonates, denosumab, and sometimes anabolics (teriparatide/abaloparatide/romosozumab) under specialist care. BioMed CentralPubMed

6) Is romosozumab a cure?
No. It may help BMD; HCS data are early case reports only. SpringerLink

7) Are stem-cell or gene therapies available now?
Not for routine care. Consider only in regulated clinical trials.

8) How often should I get bone density scans?
Typically every 1–2 years, individualized by your specialist.

9) Do I need dental precautions with bone drugs?
Yes—tell your dentist. Plan extractions carefully to lower ONJ risk, especially with denosumab or IV bisphosphonates. MDPI

10) Can children exercise?
Yes—supervised, low-impact, balance-rich programs tailored to growth stage.

11) What about pregnancy?
Plan with genetics, obstetrics, and bone specialists; some drugs are contraindicated.

12) Will I need surgery?
Only for specific problems (e.g., cranio-cervical compression, severe scoliosis, dental loss). Decisions are multidisciplinary.

13) Why do I have gum disease and early tooth loss?
Alveolar bone can resorb, and periodontal tissues are vulnerable in HCS; intensive hygiene and frequent care help. PubMed

14) How is HCS diagnosed?
By clinical features (acro-osteolysis, craniofacial/skull findings, osteoporosis) plus genetic testing for NOTCH2 variants. PMC

15) What specialists should I see?
Genetics, endocrinology/metabolic bone, orthopedics/neurosurgery, physiotherapy/OT, dentistry/periodontology, audiology, and nephrology if cysts are present.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 05, 2025.